Developer docs
API playgroundTry for free, no card

Search company profiles

Wilson Wolf Corporation

Full company profile

uuid0000nrb

Namestring
Wilson Wolf Corporation
Legal namestring
Wilson Wolf Manufacturing LLC
Websiteurl
wilsonwolf.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Wilson Wolf Corporation (legal entity: Wilson Wolf Manufacturing LLC) is a privately held Minnesota-based medical device manufacturer founded in 1998 that develops the G-Rex (Gas Permeable Rapid Expansion) line of mammalian cell culture devices. The G-Rex platform is built on a patented scientific insight that convection, rather than diffusion, governs nutrient transport to cells: a gas permeable membrane at the base of each device enables cells to sit beneath an unconventionally high column of medium, receiving oxygen and nutrients on demand without pumps, mixing, shaking, or perfusion. The product portfolio spans small-scale research plates (G-Rex24/6 Well) through mid-scale (G-Rex5M–100M) and large-scale (G-Rex500M) bioreactors, with closed-system (CS) variants for clinical and commercial GMP manufacturing, tumor fragment (TF) variants for TIL workflows, and the GatheRex automated harvest pump as a supporting instrument. The primary use cases are cell and gene therapy manufacturing — CAR-T, TCR, TIL, NK, Treg, CIK, and HSC therapies — where G-Rex competes against rocker bioreactors, hollow-fiber systems, and stirred-tank bioreactors with demonstrated cost, labor, and time advantages.

The company's revenue model combines direct unit sales of disposable G-Rex devices (ranging from approximately $108 per well plate to $8,050 per large-scale bioreactor pack) with participation in the ScaleReady joint venture, an equal partnership with Bio-Techne and Fresenius Kabi launched in 2021 that integrates G-Rex with GMP reagents and automated cell processing into an end-to-end CGT manufacturing platform. Wilson Wolf sells exclusively through direct channels (phone, email, fax) to enterprise CGT developers, academic medical centers, and CDMOs, with technical support routed through ScaleReady. The customer base exceeds 800 CGT entities globally. In March 2023, Bio-Techne invested $257 million for a 20% stake at a $1.285 billion post-money valuation after Wilson Wolf met a $55 million trailing 12-month EBITDA target, with a contingent $1 billion buyout option tied to $226 million revenue or $136 million EBITDA by December 31, 2027. Founder John Wilson additionally established CellReady, a G-Rex-centric CDMO, in 2023 to extend the platform into contract manufacturing services.

Short descriptiontext

Wilson Wolf Corporation is a privately held Minnesota manufacturer founded in 1998 that develops G-Rex, a patented gas-permeable cell culture platform used by more than 800 cell and gene therapy developers, academic centers, and CDMOs worldwide for CAR-T, TIL, NK, and other immune cell therapy manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaint Paul, United States
HQ citystring
Saint Paul
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell culture devices, bioreactor products, cell therapy manufacturing, gas permeable technology, mammalian cell expansion
Industry2 codes
PRIMARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAIAC
General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cell Culture Bioreactor Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1G-Rex Cell Culture Device Sales
TypeOne Time License
Description

Wilson Wolf generates revenue through the sale of its G-Rex cell culture products — disposable, single-use devices ranging from small well plates (G-Rex24 Well, G-Rex6 Well) to large-scale bioreactors (G-Rex500M). Products are registered as Class I medical devices and sold directly to CGT developers, academic institutions, and CDMOs. Pricing ranges from ~$108 per unit for small well plates to ~$8,050 per 2-pack for large-scale bioreactors. The company has experienced an average annual sales growth rate of nearly 100% over the last 5 years (as of early 2023).

wilsonwolf.com
2ScaleReady Joint Venture (Platform Royalties/Revenue Share)
TypeManaged Services
Description

ScaleReady is a joint venture equally owned by Bio-Techne, Fresenius Kabi, and Wilson Wolf. It provides a G-Rex-centric CGT manufacturing platform combining Wilson Wolf's G-Rex technology, Bio-Techne's GMP proteins/reagents/media, and Fresenius Kabi's cell processing systems. ScaleReady generates revenue through sales, marketing, and application support for the integrated platform globally.

wilsonwolf.com
3G-Rex Grant Program (Customer Adoption Support)
TypeProfessional Services
Description

ScaleReady, in collaboration with Wilson Wolf Manufacturing, operates the G-Rex Grant program with over $40 million in commitments to facilitate customer adoption of the G-Rex platform. These are non-dilutive grants awarded to investigators and companies (e.g., Sonoma Biotherapeutics $300,000, Children's National Hospital $375,000 total, Sidra Medicine $100,000, Immuneel Therapeutics $150,000) to support their transition to or use of the G-Rex manufacturing platform.

wilsonwolf.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Small-Scale Research Products (Well Plates)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

G-Rex24 Well Plate (P/N 80192M): $108.67 each (individual); G-Rex6 Well Plate (P/N 80240M): $108.67 each (individual); G-Rex6M 2cm² Well Plate (P/N 80120M): $417.06 each (individual); G-Rex6M 5cm² Well Plate (P/N 80300M): $417.06 each (individual); G-Rex6M 10cm² Well Plate (P/N 80660M): $417.06 each (individual). All sold individually, gamma irradiated, research use only.

wilsonwolf.com
2Mid-Scale Products (5M–100M Series)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

G-Rex5M Open System RUO (RU80055): $1,076.94 per 3-pack; G-Rex5M Sterile (80055): $1,346.16 per 3-pack; G-Rex10 Open System (80040S): $5,159.49 per 12-pack; G-Rex10M RUO (80110S): $1,031.89 per 3-pack; G-Rex10M Sterile (80110): $1,289.87 per 3-pack; G-Rex10M-CS Closed RUO (80110S-CS): $1,702.64 per 3-pack; G-Rex10M-CS Closed Sterile (80110-CS): $2,579.74 per 3-pack; G-Rex50M RUO (RU80550): $1,159.25 per 3-pack; G-Rex50M Sterile (80550): $1,449.06 per 3-pack; G-Rex50M-CS Closed RUO (RU80550-CS): $1,912.76 per 3-pack; G-Rex50M-CS Closed Sterile (80550-CS): $2,898.12 per 3-pack; G-Rex50M-TF RUO (RU80550-TF): $2,008.39 per 3-pack; G-Rex50M-TF Sterile (80550-TF): $3,043.02 per 3-pack.

wilsonwolf.com
3Large-Scale Products (100–500M Series)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

G-Rex100 Sterile (80500): $1,618.22 per 3-pack; G-Rex100M RUO (RU81100): $1,294.56 per 3-pack; G-Rex100M Sterile (81100): $1,618.22 per 3-pack; G-Rex100M-CS Closed RUO (RU81100-CS): $2,136.06 per 3-pack; G-Rex100M-CS Closed Sterile (81100-CS): $3,236.43 per 3-pack; G-Rex500M RUO (G285500-RU): $3,066.65 per 2-pack; G-Rex500M Sterile (G285500): $3,833.33 per 2-pack; G-Rex500M-CS Closed RUO (RUO5500-CS): $5,060.03 per 2-pack; G-Rex500M-CS Closed Sterile (G285500-CS): $7,666.64 per 2-pack; G-Rex500M-TF RUO (RU85500-TF): $5,313.02 per 2-pack; G-Rex500M-TF Sterile (G285500-TF): $8,049.98 per 2-pack.

wilsonwolf.com
4Accessories and Consumables
ModelUnit PricingBilling cadencePay-as-you-go
Notes

GatheRex Cell Harvest Pump (P/N 80000E or 80000Z): $29,787.00 (ETL certified, 2-year warranty); G-Rex 250mL Processing Bag (WW-FP250ML): $57.96 per bag; G-Rex 1L Processing Bag (WW-SV1L444): $159.00 per bag; G-Rex 5L Processing Bag (WW-SV5L844N): $270.38 per bag; G-Rex10 Series Support Base (AY14-2008): $33.04 per 3-pack; G-Rex Cap 48mm (11-00036/S): $11.01 each.

wilsonwolf.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Wilson Wolf Corporation develops and manufactures the G-Rex (Gas Permeable Rapid Expansion) line of proprietary mammalian cell culture devices used in cell and gene therapy (CGT) manufacturing. The G-Rex platform is based on gas permeable membrane technology that enables convection-driven nutrient transport to cells without pumps, mixing, or shaking. Products are sold as Class I medical devices directly to CGT developers, academic medical centers, and contract development and manufacturing organizations (CDMOs).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Can turn 300 million cells into 100 billion cells in just 11 days (shortest possible production cycle for T-cell therapies)
+4 more records
Product overview1 text field

Wilson Wolf Corporation offers the G-Rex (Gas Permeable Rapid Expansion) line of cell culture devices, a unified platform of disposable, single-use bioreactors for cell and gene therapy manufacturing. The portfolio spans from small-scale research devices (24 Well Plates, 6 Well Plates, 5M, 10, 10M) to clinical and commercial-scale systems (100, 100M, 500M), with closed system variants (CS series) featuring semi-automated liquid handling, and tumor fragment models (TF series) for TIL therapy. The G-Rex platform uses a proprietary gas permeable membrane technology that allows cells to receive oxygen and nutrients on demand without perfusion, mixing, or shaking. Accessories include the GatheRex Cell Harvest Pump for automated cell concentration and G-Rex Processing Bags. The company operates through ScaleReady, a joint venture with Bio-Techne and Fresenius Kabi, providing an integrated CGT manufacturing platform combining G-Rex cell culture with cell activation, gene editing, and cell processing technologies.

Product and service16 records
1G-Rex 24 Well Plate
CategoryCell Culture Device
Description

Gas permeable cell culture device with 2cm² membrane and 8mL media capacity, designed to expand 1 million cells into 40-80 million cells in about 12 days with two medium exchanges. Targeted at research-scale applications.

2G-Rex 6 Well Plate
CategoryCell Culture Device
Description

Gas permeable cell culture device with 10cm² membrane and 40mL media capacity, designed to expand 5 million cells into 200-400 million cells in about 12 days with two medium exchanges. For research-scale applications.

3G-Rex 6M Well Plates
CategoryCell Culture Device
Description

High cell density gas permeable multi-well plates (2cm², 5cm², and 10cm² variants) using optimized 10mL/cm² media-to-surface ratio, enabling cell expansion without medium exchange in approximately 10 days.

4G-Rex 5M
CategoryCell Culture Device
Description

Gas permeable rapid expansion device with 5cm² membrane and 50mL media capacity; expands 2.5 million cells into 100-200 million cells in about 10 days with no medium exchange.

5G-Rex 10
CategoryCell Culture Device
Description

Gas permeable rapid expansion device with 10cm² membrane and 40mL media capacity; expands 5 million cells into 200-400 million cells in about 12 days with two medium exchanges.

6G-Rex 10M
CategoryCell Culture Device
Description

High cell density gas permeable rapid expansion device with 10cm² membrane and 100mL media capacity using optimal 10mL/cm² ratio; expands 5 million cells into 200-400 million cells in about 10 days with no medium exchange.

7G-Rex 10M-CS (Closed System)
CategoryCell Culture Device
Description

Closed system gas permeable rapid expansion device with 10cm² membrane and 100mL media capacity, featuring semi-automated liquid handling for clinical-grade cell expansion.

8G-Rex 50M
CategoryCell Culture Device
Description

High cell density gas permeable rapid expansion device with 50cm² membrane and 500mL media capacity; expands 25 million cells into 1-2 billion cells in about 10 days with no medium exchange.

9G-Rex 50M-CS (Closed System)
CategoryCell Culture Device
Description

Closed system high cell density gas permeable rapid expansion device with 50cm² membrane and 500mL media capacity, featuring semi-automated liquid handling for large-scale clinical cell expansion.

10G-Rex 50M-TF (Tumor Fragment Closed System)
CategoryCell Culture Device
Description

Closed system gas permeable rapid expansion device with 50cm² membrane and 500mL media capacity, featuring a removable cap designed for tumor fragment addition for tumor-infiltrating lymphocyte (TIL) therapy applications.

11G-Rex 100
CategoryCell Culture Device
Description

Gas permeable rapid expansion device with 100cm² membrane and 450mL media capacity; expands 50 million cells into 2-4 billion cells in about 12 days with two medium exchanges.

12G-Rex 100M
CategoryCell Culture Device
Description

High cell density gas permeable rapid expansion device with 100cm² membrane and 1000mL media capacity; expands 50 million cells into 2-4 billion cells in about 10 days with no medium exchange.

13G-Rex 100M-CS (Closed System)
CategoryCell Culture Device
Description

Closed system high cell density gas permeable rapid expansion device with 100cm² membrane and 1000mL media capacity, featuring semi-automated liquid handling for commercial-scale clinical cell expansion. The G-Rex100M-CS provides 2-4 billion cells in about 10 days with no medium exchange.

14G-Rex 500M
CategoryCell Culture Device
Description

High cell density gas permeable rapid expansion device with 500cm² membrane and 5000mL media capacity; expands 250 million cells into 10-20 billion cells in about 10 days with no medium exchange.

15G-Rex 500M-CS (Closed System)
CategoryCell Culture Device
Description

Closed system high cell density gas permeable rapid expansion device with 500cm² membrane and 5000mL media capacity, featuring semi-automated liquid handling for large-scale commercial cell therapy manufacturing.

16G-Rex 500M-TF (Tumor Fragment Closed System)
CategoryCell Culture Device
Description

Closed system gas permeable rapid expansion device with 500cm² membrane and 5000mL media capacity, featuring removable cap for tumor fragment addition and semi-automated cell harvest with GatheRex Pump for TIL therapy manufacturing.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1CellReady
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-01
Description

CellReady is a Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, who is also the founder and CEO of Wilson Wolf Corporation and Marker Therapeutics Co-Founder and Board Member. CellReady acquired certain cell manufacturing assets from Marker Therapeutics for approximately $19 million in cash (transaction closed June 26, 2023) and employs Marker's manufacturing, development, quality, and regulatory affairs personnel. CellReady enters into long-term service agreements with Marker to perform R&D, manufacturing, and regulatory activities. CellReady's mission is to radically improve the CGT business model by providing a standard G-Rex-centric cell manufacturing platform, manufacturing protocols, quality management system, and CMC section sanctioned by the FDA.

wilsonwolf.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-21
Description

ScaleReady is a joint venture equally owned by Bio-Techne Corporation, Fresenius Kabi, and Wilson Wolf Manufacturing. Announced January 2020 (formation) and formally launched January 2021, ScaleReady integrates the partners' complementary technologies — Wilson Wolf's G-Rex cell culture, Fresenius Kabi's Lovo and upcoming Cue cell processing systems, and Bio-Techne's GMP proteins, reagents, media, and gene editing technologies — into a unified CGT manufacturing platform covering the full spectrum from R&D to commercial drug product manufacturing. The platform is designed to be the most simple, scalable, and versatile in the industry, enabling CGT companies to save at least 2 years of time and millions of dollars.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-01-21
Description

Fresenius Kabi is one of the three equal co-owners of the ScaleReady joint venture alongside Bio-Techne and Wilson Wolf. Fresenius Kabi contributes its Lovo cell processing system (washes, concentrates, and harvests cells at clinical and commercial scale) and its upcoming Cue cell processing system to the ScaleReady platform. Fresenius Kabi brings expertise in automated cell processing and closed-system development to the partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global life-science tools leader (formerly GE Healthcare Life Sciences) offering Xuri cell expansion systems, rocking-motion bioreactors, and single-use cell culture consumables used in CGT manufacturing. Comparable to Wilson Wolf as an upstream supplier of bioreactor systems, but with a much broader portfolio across modalities.

TypeBroad incumbent
Description

Major bioprocessing supplier of single-use bioreactors (e.g., Biostat RM, Biostat B) and cell therapy process solutions. Comparable as a CGT manufacturing equipment incumbent competing for the same cell-expansion workflow dollars.

TypeBroad incumbent
Description

Global CDMO and bioprocessing technology provider offering cell therapy manufacturing services and equipment (Cocoon, Modulus). Comparable as both a CGT process technology provider and a CDMO customer of upstream cell culture platforms.

TypeDirect peer
Description

Provides the Prodigy and CliniMACS cell processing and expansion systems used across CGT manufacturing. Directly comparable to G-Rex as a workflow anchor for T-cell, CAR-T, and gene-edited cell therapy production.

TypeBroad incumbent
Description

Supplies Gibco cell culture media, sera, and consumables as well as the CTS Rotea counterflow centrifugation system for cell therapy. Comparable as a critical CGT upstream supplier competing for share of the cell and gene therapy manufacturing workflow.

TypeDirect peer
Description

Provides the Quantum Cell Expansion System and Finia fill/finish system used in cell therapy manufacturing. Directly comparable to G-Rex as a cell expansion platform serving similar CAR-T and stem cell therapy customers.

TypeEmerging player
Description

Emerging automated cell therapy manufacturing platform (Cell Shuttle) targeting integrated, high-throughput CAR-T production. Comparable to G-Rex as a next-generation CGT manufacturing platform, with a stronger automation thesis.

TypeEmerging player
Description

Develops an automated, closed-system cell and gene therapy manufacturing platform (Iro) targeting scalable CGT production. Comparable to G-Rex as a workflow competitor, with a more automation-heavy approach.

TypeDirect peer
Description

Supplies cell culture media, reagents, and instruments for stem cell and immune cell workflows used in CGT R&D and manufacturing. Comparable to Wilson Wolf as a supplier into cell therapy laboratories with overlapping customer segments.

TypeOthers
Description

Strategic minority investor and ScaleReady JV partner providing GMP proteins, reagents, media, and gene editing tools for CGT. Comparable as a co-developer of the integrated ScaleReady platform and a proxy for how a strategic acquirer would value G-Rex.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wilson Wolf Corporation

Cell Culture Bioreactor Deviceswilsonwolf.com

Wilson Wolf Corporation is a privately held Minnesota manufacturer founded in 1998 that develops G-Rex, a patented gas-permeable cell culture platform used by more than 800 cell and gene therapy developers, academic centers, and CDMOs worldwide for CAR-T, TIL, NK, and other immune cell therapy manufacturing.

What Wilson Wolf Corporation does

Wilson Wolf Corporation (legal entity: Wilson Wolf Manufacturing LLC) is a privately held Minnesota-based medical device manufacturer founded in 1998 that develops the G-Rex (Gas Permeable Rapid Expansion) line of mammalian cell culture devices. The G-Rex platform is built on a patented scientific insight that convection, rather than diffusion, governs nutrient transport to cells: a gas permeable membrane at the base of each device enables cells to sit beneath an unconventionally high column of medium, receiving oxygen and nutrients on demand without pumps, mixing, shaking, or perfusion. The product portfolio spans small-scale research plates (G-Rex24/6 Well) through mid-scale (G-Rex5M–100M) and large-scale (G-Rex500M) bioreactors, with closed-system (CS) variants for clinical and commercial GMP manufacturing, tumor fragment (TF) variants for TIL workflows, and the GatheRex automated harvest pump as a supporting instrument. The primary use cases are cell and gene therapy manufacturing — CAR-T, TCR, TIL, NK, Treg, CIK, and HSC therapies — where G-Rex competes against rocker bioreactors, hollow-fiber systems, and stirred-tank bioreactors with demonstrated cost, labor, and time advantages.

The company's revenue model combines direct unit sales of disposable G-Rex devices (ranging from approximately $108 per well plate to $8,050 per large-scale bioreactor pack) with participation in the ScaleReady joint venture, an equal partnership with Bio-Techne and Fresenius Kabi launched in 2021 that integrates G-Rex with GMP reagents and automated cell processing into an end-to-end CGT manufacturing platform. Wilson Wolf sells exclusively through direct channels (phone, email, fax) to enterprise CGT developers, academic medical centers, and CDMOs, with technical support routed through ScaleReady. The customer base exceeds 800 CGT entities globally. In March 2023, Bio-Techne invested $257 million for a 20% stake at a $1.285 billion post-money valuation after Wilson Wolf met a $55 million trailing 12-month EBITDA target, with a contingent $1 billion buyout option tied to $226 million revenue or $136 million EBITDA by December 31, 2027. Founder John Wilson additionally established CellReady, a G-Rex-centric CDMO, in 2023 to extend the platform into contract manufacturing services.

Wilson Wolf Corporation firmographics

Firmographics
Name
Wilson Wolf Corporation
Legal name
Wilson Wolf Manufacturing LLC
Website
https://wilsonwolf.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Short description
Wilson Wolf Corporation is a privately held Minnesota manufacturer founded in 1998 that develops G-Rex, a patented gas-permeable cell culture platform used by more than 800 cell and gene therapy developers, academic centers, and CDMOs worldwide for CAR-T, TIL, NK, and other immune cell therapy manufacturing.
Ownership category
akta.pro rank

Wilson Wolf Corporation industry classification

Industry
Product category
Cell Culture Bioreactor Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAIAC
General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens)

Keywords

  • Cell culture devices
  • Bioreactor products
  • Cell therapy manufacturing
  • Gas permeable technology
  • Mammalian cell expansion

Where Wilson Wolf Corporation is headquartered

Location

Headquarters

HQ city
Saint Paul
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Wilson Wolf Corporation business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. G-Rex Cell Culture Device Sales: Wilson Wolf generates revenue through the sale of its G-Rex cell culture products — disposable, single-use devices ranging from small well plates (G-Rex24 Well, G-Rex6 Well) to large-scale bioreactors (G-Rex500M). Products are registered as Class I medical devices and sold directly to CGT developers, academic institutions, and CDMOs. Pricing ranges from ~$108 per unit for small well plates to ~$8,050 per 2-pack for large-scale bioreactors. The company has experienced an average annual sales growth rate of nearly 100% over the last 5 years (as of early 2023).
  2. ScaleReady Joint Venture (Platform Royalties/Revenue Share): ScaleReady is a joint venture equally owned by Bio-Techne, Fresenius Kabi, and Wilson Wolf. It provides a G-Rex-centric CGT manufacturing platform combining Wilson Wolf's G-Rex technology, Bio-Techne's GMP proteins/reagents/media, and Fresenius Kabi's cell processing systems. ScaleReady generates revenue through sales, marketing, and application support for the integrated platform globally.
  3. G-Rex Grant Program (Customer Adoption Support): ScaleReady, in collaboration with Wilson Wolf Manufacturing, operates the G-Rex Grant program with over $40 million in commitments to facilitate customer adoption of the G-Rex platform. These are non-dilutive grants awarded to investigators and companies (e.g., Sonoma Biotherapeutics $300,000, Children's National Hospital $375,000 total, Sidra Medicine $100,000, Immuneel Therapeutics $150,000) to support their transition to or use of the G-Rex manufacturing platform.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSmall-Scale Research Products (Well Plates)
Unit PricingPay-as-you-goMid-Scale Products (5M–100M Series)
Unit PricingPay-as-you-goLarge-Scale Products (100–500M Series)
Unit PricingPay-as-you-goAccessories and Consumables

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Wilson Wolf Corporation product offering

Product offering

Core offering

Wilson Wolf Corporation develops and manufactures the G-Rex (Gas Permeable Rapid Expansion) line of proprietary mammalian cell culture devices used in cell and gene therapy (CGT) manufacturing. The G-Rex platform is based on gas permeable membrane technology that enables convection-driven nutrient transport to cells without pumps, mixing, or shaking. Products are sold as Class I medical devices directly to CGT developers, academic medical centers, and contract development and manufacturing organizations (CDMOs).

Product overview

Wilson Wolf Corporation offers the G-Rex (Gas Permeable Rapid Expansion) line of cell culture devices, a unified platform of disposable, single-use bioreactors for cell and gene therapy manufacturing. The portfolio spans from small-scale research devices (24 Well Plates, 6 Well Plates, 5M, 10, 10M) to clinical and commercial-scale systems (100, 100M, 500M), with closed system variants (CS series) featuring semi-automated liquid handling, and tumor fragment models (TF series) for TIL therapy. The G-Rex platform uses a proprietary gas permeable membrane technology that allows cells to receive oxygen and nutrients on demand without perfusion, mixing, or shaking. Accessories include the GatheRex Cell Harvest Pump for automated cell concentration and G-Rex Processing Bags. The company operates through ScaleReady, a joint venture with Bio-Techne and Fresenius Kabi, providing an integrated CGT manufacturing platform combining G-Rex cell culture with cell activation, gene editing, and cell processing technologies.

Differentiator

Problem solved

Functional benefit

Products and services

  • G-Rex 24 Well Plate Gas permeable cell culture device with 2cm² membrane and 8mL media capacity, designed to expand 1 million cells into 40-80 million cells in about 12 days with two medium exchanges. Targeted at research-scale applications.
  • G-Rex 6 Well Plate Gas permeable cell culture device with 10cm² membrane and 40mL media capacity, designed to expand 5 million cells into 200-400 million cells in about 12 days with two medium exchanges. For research-scale applications.
  • G-Rex 6M Well Plates High cell density gas permeable multi-well plates (2cm², 5cm², and 10cm² variants) using optimized 10mL/cm² media-to-surface ratio, enabling cell expansion without medium exchange in approximately 10 days.
  • G-Rex 5M Gas permeable rapid expansion device with 5cm² membrane and 50mL media capacity; expands 2.5 million cells into 100-200 million cells in about 10 days with no medium exchange.
  • G-Rex 10 Gas permeable rapid expansion device with 10cm² membrane and 40mL media capacity; expands 5 million cells into 200-400 million cells in about 12 days with two medium exchanges.
  • G-Rex 10M High cell density gas permeable rapid expansion device with 10cm² membrane and 100mL media capacity using optimal 10mL/cm² ratio; expands 5 million cells into 200-400 million cells in about 10 days with no medium exchange.
  • G-Rex 10M-CS (Closed System) Closed system gas permeable rapid expansion device with 10cm² membrane and 100mL media capacity, featuring semi-automated liquid handling for clinical-grade cell expansion.
  • G-Rex 50M High cell density gas permeable rapid expansion device with 50cm² membrane and 500mL media capacity; expands 25 million cells into 1-2 billion cells in about 10 days with no medium exchange.
  • G-Rex 50M-CS (Closed System) Closed system high cell density gas permeable rapid expansion device with 50cm² membrane and 500mL media capacity, featuring semi-automated liquid handling for large-scale clinical cell expansion.
  • G-Rex 50M-TF (Tumor Fragment Closed System) Closed system gas permeable rapid expansion device with 50cm² membrane and 500mL media capacity, featuring a removable cap designed for tumor fragment addition for tumor-infiltrating lymphocyte (TIL) therapy applications.
  • G-Rex 100 Gas permeable rapid expansion device with 100cm² membrane and 450mL media capacity; expands 50 million cells into 2-4 billion cells in about 12 days with two medium exchanges.
  • G-Rex 100M High cell density gas permeable rapid expansion device with 100cm² membrane and 1000mL media capacity; expands 50 million cells into 2-4 billion cells in about 10 days with no medium exchange.
  • G-Rex 100M-CS (Closed System) Closed system high cell density gas permeable rapid expansion device with 100cm² membrane and 1000mL media capacity, featuring semi-automated liquid handling for commercial-scale clinical cell expansion. The G-Rex100M-CS provides 2-4 billion cells in about 10 days with no medium exchange.
  • G-Rex 500M High cell density gas permeable rapid expansion device with 500cm² membrane and 5000mL media capacity; expands 250 million cells into 10-20 billion cells in about 10 days with no medium exchange.
  • G-Rex 500M-CS (Closed System) Closed system high cell density gas permeable rapid expansion device with 500cm² membrane and 5000mL media capacity, featuring semi-automated liquid handling for large-scale commercial cell therapy manufacturing.
  • G-Rex 500M-TF (Tumor Fragment Closed System) Closed system gas permeable rapid expansion device with 500cm² membrane and 5000mL media capacity, featuring removable cap for tumor fragment addition and semi-automated cell harvest with GatheRex Pump for TIL therapy manufacturing.

Quantifiable outcome

  • Can turn 300 million cells into 100 billion cells in just 11 days (shortest possible production cycle for T-cell therapies)
  • +4 more outcomes

Companies that use Wilson Wolf Corporation

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Wilson Wolf Corporation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Wilson Wolf Corporation partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • CellReadycoreStrategic or Co-development Partner · 1 May 2023CellReady is a Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, who is also the founder and CEO of Wilson Wolf Corporation and Marker Therapeutics Co-Founder and Board Member. CellReady acquired certain cell manufacturing assets from Marker Therapeutics for approximately $19 million in cash (transaction closed June 26, 2023) and employs Marker's manufacturing, development, quality, and regulatory affairs personnel. CellReady enters into long-term service agreements with Marker to perform R&D, manufacturing, and regulatory activities. CellReady's mission is to radically improve the CGT business model by providing a standard G-Rex-centric cell manufacturing platform, manufacturing protocols, quality management system, and CMC section sanctioned by the FDA.
  • ScaleReady (Bio-Techne + Fresenius Kabi + Wilson Wolf)coreStrategic or Co-development Partner · 21 January 2020ScaleReady is a joint venture equally owned by Bio-Techne Corporation, Fresenius Kabi, and Wilson Wolf Manufacturing. Announced January 2020 (formation) and formally launched January 2021, ScaleReady integrates the partners' complementary technologies — Wilson Wolf's G-Rex cell culture, Fresenius Kabi's Lovo and upcoming Cue cell processing systems, and Bio-Techne's GMP proteins, reagents, media, and gene editing technologies — into a unified CGT manufacturing platform covering the full spectrum from R&D to commercial drug product manufacturing. The platform is designed to be the most simple, scalable, and versatile in the industry, enabling CGT companies to save at least 2 years of time and millions of dollars.
  • Fresenius KabicoreTechnology or Integration · 21 January 2020Fresenius Kabi is one of the three equal co-owners of the ScaleReady joint venture alongside Bio-Techne and Wilson Wolf. Fresenius Kabi contributes its Lovo cell processing system (washes, concentrates, and harvests cells at clinical and commercial scale) and its upcoming Cue cell processing system to the ScaleReady platform. Fresenius Kabi brings expertise in automated cell processing and closed-system development to the partnership.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Wilson Wolf Corporation competitors and assessment

Company assessment

Broad incumbents

  • Cytiva: Global life-science tools leader (formerly GE Healthcare Life Sciences) offering Xuri cell expansion systems, rocking-motion bioreactors, and single-use cell culture consumables used in CGT manufacturing. Comparable to Wilson Wolf as an upstream supplier of bioreactor systems, but with a much broader portfolio across modalities.
  • Sartorius: Major bioprocessing supplier of single-use bioreactors (e.g., Biostat RM, Biostat B) and cell therapy process solutions. Comparable as a CGT manufacturing equipment incumbent competing for the same cell-expansion workflow dollars.
  • Lonza: Global CDMO and bioprocessing technology provider offering cell therapy manufacturing services and equipment (Cocoon, Modulus). Comparable as both a CGT process technology provider and a CDMO customer of upstream cell culture platforms.
  • Thermo Fisher Scientific (Gibco Cell Culture): Supplies Gibco cell culture media, sera, and consumables as well as the CTS Rotea counterflow centrifugation system for cell therapy. Comparable as a critical CGT upstream supplier competing for share of the cell and gene therapy manufacturing workflow.

Direct peers

  • Miltenyi Biotec: Provides the Prodigy and CliniMACS cell processing and expansion systems used across CGT manufacturing. Directly comparable to G-Rex as a workflow anchor for T-cell, CAR-T, and gene-edited cell therapy production.
  • Terumo BCT: Provides the Quantum Cell Expansion System and Finia fill/finish system used in cell therapy manufacturing. Directly comparable to G-Rex as a cell expansion platform serving similar CAR-T and stem cell therapy customers.
  • StemCell Technologies: Supplies cell culture media, reagents, and instruments for stem cell and immune cell workflows used in CGT R&D and manufacturing. Comparable to Wilson Wolf as a supplier into cell therapy laboratories with overlapping customer segments.

Emerging players

  • Cellares: Emerging automated cell therapy manufacturing platform (Cell Shuttle) targeting integrated, high-throughput CAR-T production. Comparable to G-Rex as a next-generation CGT manufacturing platform, with a stronger automation thesis.
  • Ori Biotech: Develops an automated, closed-system cell and gene therapy manufacturing platform (Iro) targeting scalable CGT production. Comparable to G-Rex as a workflow competitor, with a more automation-heavy approach.

Others

  • Bio-Techne: Strategic minority investor and ScaleReady JV partner providing GMP proteins, reagents, media, and gene editing tools for CGT. Comparable as a co-developer of the integrated ScaleReady platform and a proxy for how a strategic acquirer would value G-Rex.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Wilson Wolf Corporation social profiles

Digital presence

Wilson Wolf Corporation compliance and trust

Trust signal

Compliance1 record

Wilson Wolf Corporation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wilson Wolf Corporation leadership team

Management profile

Number of profiles

Profiles1 record

Wilson Wolf Corporation subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Wilson Wolf Corporation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wilson Wolf Corporation M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wilson Wolf Corporation

What does Wilson Wolf Corporation do?

Wilson Wolf Corporation develops and manufactures the G-Rex (Gas Permeable Rapid Expansion) line of proprietary mammalian cell culture devices used in cell and gene therapy (CGT) manufacturing. The G-Rex platform is based on gas permeable membrane technology that enables convection-driven nutrient transport to cells without pumps, mixing, or shaking. Products are sold as Class I medical devices directly to CGT developers, academic medical centers, and contract development and manufacturing organizations (CDMOs).

Is Wilson Wolf Corporation a public or private company?

Wilson Wolf Corporation is a private company. It is classified as venture growth investor backed and is currently operating.

When was Wilson Wolf Corporation founded?

Wilson Wolf Corporation was founded in 1998. It employs 11 to 50 people.

Where is Wilson Wolf Corporation based?

Wilson Wolf Corporation is headquartered in Saint Paul, United States, in the North America region.

How does Wilson Wolf Corporation make money?

Three revenue lines are on record. G-Rex Cell Culture Device Sales are the primary driver. The others are scaleReady Joint Venture (Platform Royalties/Revenue Share) and G-Rex Grant Program (Customer Adoption Support).

Who are Wilson Wolf Corporation's main competitors?

Broad incumbents on record are Cytiva, Sartorius, Lonza and Thermo Fisher Scientific (Gibco Cell Culture). Direct peers are Miltenyi Biotec, Terumo BCT and StemCell Technologies. Emerging players are Cellares and Ori Biotech. Bio-Techne is listed as an others.

Does Wilson Wolf Corporation have an API?

No public API is recorded for Wilson Wolf Corporation.

What industry is Wilson Wolf Corporation in?

Wilson Wolf Corporation's product category is Cell Culture Bioreactor Devices. Its primary akta.pro industry code is HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies, with a secondary code of HLAGAIAC, General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceHemogenyx Awarded GrantHemogenyx Pharmaceuticals received a $120,000 G-Rex grant from ScaleReady, Wilson Wolf, and Cell Ready to optimize manufacturing for its CAR-T candidate HG-CT-1. The grant aims to reduce per-patient costs and support future G-Rex M series bioreactor adoption.PharmiWeb.comHemogenyx Awarded GrantHemogenyx Pharmaceuticals received a $120,000 G-Rex grant from ScaleReady, Wilson Wolf, and Cell Ready to optimize manufacturing for its lead CAR-T candidate HG-CT-1. The grant aims to reduce production complexity and lower per-patient costs, supporting the product's commercial viability.ScalereadyG-Rex Grant ProgramThe G-Rex Grant Program is a $30 million initiative aimed at advancing cell and gene therapies, launched by ScaleReady, Wilson Wolf Manufacturing, Bio-Techne, and CellReady. Over 250 groups engaged in pre-clinical research and manufacturing of modified cell therapies are benefiting from this program, which provides funding and resources for efficient manufacturing transitions. Although submissions for the program are now closed, ScaleReady continues to offer support and resources to the industry.Investing.comImmunoScape secures $250,000 G-Rex grant for therapy By Investing.comImmunoScape Pte. Ltd. has received a $250,000 G-Rex Grant from ScaleReady, Wilson Wolf Manufacturing, and Bio-Techne Corporation to develop its WT1-targeted therapy. The grant will aid in expediting process development and regulatory studies for clinical introduction of the therapy, with a goal for an IND submission to the FDA by 2026.ScalereadyMultiply Labs and Wilson Wolf Join Forces to Automate Cell Therapy Manufacturing with G-Rex® BioreactorsMultiply Labs and Wilson Wolf have partnered to automate cell therapy manufacturing using G-Rex® bioreactors. This collaboration aims to address challenges in scaling Natural Killer (NK) cell production for cancer immunotherapy treatments.BioSpaceBio-Techne Completes Investment in Wilson Wolf ManufacturingBio-Techne completed its investment in Wilson Wolf Manufacturing, achieving the $55 million EBITDA target that triggered the initial investment. The $257 million investment gives Bio-Techne a 20% stake, with a right to acquire the remaining stake for $1 billion upon meeting revenue or EBITDA milestones. Wilson Wolf's G-Rex cell production technology is used by over 800 CGT market participants.PR NewswireBIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURINGBio-Techne Corporation has completed a $257 million investment to acquire a 20% ownership stake in Wilson Wolf Manufacturing after the latter met its EBITDA targets. The agreement includes an option for Bio-Techne to acquire the remaining shares for $1 billion if specific revenue or profitability milestones are achieved by December 31, 2027. This transaction strengthens Bio-Techne's position in the cell and gene therapy manufacturing sector through Wilson Wolf's proprietary G-Rex technology.Roots AnalysisGlobal Fermenters and Bioreactors Market Size Report, [2035]The global fermenters and bioreactors market is projected to grow from USD 25.9 billion in 2025 to USD 73.7 billion by 2035, driven by rising demand for biologics and advancements in bioprocessing technologies. Key industry developments include strategic partnerships between companies like Culture Biosciences and Google Cloud, as well as Wilson Wolf and Multiply Labs, aimed at integrating AI and automation into manufacturing processes.Star TribuneBio-Techne will invest $257 million in New Brighton med-tech companyBio-Techne Corp. has agreed to invest $257 million for a 20% stake in New Brighton-based Wilson Wolf Manufacturing, with an option to acquire the remaining shares for up to $1 billion if financial targets are met. The transaction aims to expand Bio-Techne's capabilities in cell and gene therapies by integrating Wilson Wolf's device manufacturing expertise.GlobeNewswireMarker Therapeutics Reports Q2 2022 Operating and Financial ResultsMarker Therapeutics reported Q2 2022 results with a net loss of $9.2 million and cash of $25.8 million. The company received an $8 million upfront payment from Wilson Wolf and expects a topline readout of its AML study in Q3 2022. It also plans to file an IND for MT-601 in pancreatic cancer by year-end.